Peyre et al., 2015) and in neutrophils (Naisbitt et al., 1998)
a clinician's review that confirms eligibility before any prescription is written
Wegovy clinical studies and reported hair loss percentages Wegovy clinical trials show more notable results: Hair loss affected 3% of adult participants compared to 1% in the placebo group [7] The numbers were higher in children 12 and older, where 4% reported hair loss while the placebo group showed no cases [8] Comparing hair loss rates across different GLP-1 medications GLP-1 medications of all types show distinct patterns: Tirzepatide (Mounjaro): Users reported hair loss rates between 4.9% to 5.7% at doses from 5mg to 15mg [8] Zepbound: The overall rates reached 4% to 5%, with women showing much higher numbers 7.1% compared to just 0.5% in men [8] Research from the University of British Columbia shows that people who use semaglutide have a 52% higher chance of hair loss compared to those taking older weight loss medications [9]
For the right patient, especially someone struggling with cravings or pattern-based eating, this option may address a different part of the problem than appetite control alone
By activating both GLP-1 and GIP receptors, tirzepatide naturally reduces your appetite, prolongs feelings of fullness, enhances insulin sensitivity, and may boost calorie burning
You do not need to eliminate any food category entirely
